12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Evista raloxifene regulatory update

The American Society of Clinical Oncology (ASCO) issued an updated clinical practice guideline recommending the 5-year use of 3 breast cancer drugs as preventative options for women who are at increased risk for estrogen receptor-positive breast cancer. The guideline recommends that physicians discuss the use of tamoxifen with premenopausal and...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >